Clinical trial registry record

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 18, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04662944
Last registry update
June 18, 2024
Status
Completed
Phase
Phase not reported
Sponsor
Novartis Pharmaceuticals
Enrollment
494
Countries
Canada, Germany, Ireland, Italy, Spain
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
494
Population
ALL · 18 Years to 199 Years
Duration
2021-02-23 to 2023-06-28
Intervention
brolucizumab; ranibizumab; aflibercept
Comparator
Not reported
Outcomes measured
Odds ratio of disease activity assessment from Optical Coherence Tomography (OCTs) with and without enrichment — 12 mon…; Degree of agreement in classification of disease activity using enriched and non-enriched OCT images — 12 months; Difference in time needed for Disease Activity Assessment (DAA) between reviews with and without enrichment — 12 months; Difference in confidence in DAA between reviews with and without enrichment — 12 months; Acceptance of Discovery by physicians and whether it can optimize the ophthalmic clinical workflow — Month 12; Percentage of patients with absence of Subretinal Fluid, Intraretinal Fluid and Pigment Epithelium Detachment — Month 12; Central Subfield Thickness (CST) change — 12 months; Best-corrected visual acuity change from baseline — 12 months; Percentage of patients with ocular and non-ocular adverse events — 12 months; Subjective assessment of system correctness — 12 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON